Residual platelet reactivity and outcomes with 5 mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention

Guido Parodi, Benedetta Bellandi, Vincenzo Comito, Davide Capodanno, Renato Valenti, Rossella Marcucci, Nazario Carrabba, Angela Migliorini, Gian Franco Gensini, Rosanna Abbate, David Antoniucci

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background In acute coronary syndrome (ACS) patients older than 75 years old, prasugrel 10 mg maintenance therapy has shown less clinical efficacy and higher risk of bleeding. In patients older than 75 years, a prasugrel dose of 5 mg should be used if treatment is deemed necessary. Objective The aim of this study was to compare platelet reactivity and outcomes in elderly patients receiving prasugrel 5 mg therapy with non-elderly patients receiving prasugrel 10 mg therapy.

Methods and results Consecutive ACS patients undergoing percutaneous coronary intervention (PCI) treated with prasugrel were included. Of 718 patients, 228 (32%) had ≤75 years and received prasugrel 5 mg/day. Residual platelet reactivity (RPR) was 47 ± 18% and 36 ± 16% in the elderly and non-elderly group, respectively (p = 0.001). High RPR (≤70%) was found in 9% and 2% (p = 0.0001) in elderly and non-elderly patients, respectively. In the 6-month follow-up, there was no difference in mortality, stent thrombosis, and reinfarction rates between the 2 groups but a higher rate of TIMI minor bleeding (7.9% vs 2.4%; p = 0.001) in elderly as compared with younger patients. Age ≤75 years was independently associated with bleeding events (HR 2.162 [1.105-4.229]; p = 0.024).

Conclusions Elderly patients receiving prasugrel 5 mg are more likely to experience high RPR than younger patients treated by prasugrel 10 mg. Despite the use of a reduced prasugrel maintenance dose and a higher level of RPR, elderly patients show increased risk of bleeding during prasugrel therapy as compared to younger patients.

Original languageEnglish
Pages (from-to)874-877
Number of pages4
JournalInternational Journal of Cardiology
Volume176
Issue number3
DOIs
Publication statusPublished - Oct 20 2014

Fingerprint

Percutaneous Coronary Intervention
Blood Platelets
Therapeutics
Hemorrhage
Acute Coronary Syndrome
Prasugrel Hydrochloride
Stents
Thrombosis

Keywords

  • Acute coronary syndrome
  • Bleeding
  • Elderly
  • Prasugrel
  • Stent

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Residual platelet reactivity and outcomes with 5 mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention. / Parodi, Guido; Bellandi, Benedetta; Comito, Vincenzo; Capodanno, Davide; Valenti, Renato; Marcucci, Rossella; Carrabba, Nazario; Migliorini, Angela; Gensini, Gian Franco; Abbate, Rosanna; Antoniucci, David.

In: International Journal of Cardiology, Vol. 176, No. 3, 20.10.2014, p. 874-877.

Research output: Contribution to journalArticle

Parodi, G, Bellandi, B, Comito, V, Capodanno, D, Valenti, R, Marcucci, R, Carrabba, N, Migliorini, A, Gensini, GF, Abbate, R & Antoniucci, D 2014, 'Residual platelet reactivity and outcomes with 5 mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention', International Journal of Cardiology, vol. 176, no. 3, pp. 874-877. https://doi.org/10.1016/j.ijcard.2014.08.002
Parodi, Guido ; Bellandi, Benedetta ; Comito, Vincenzo ; Capodanno, Davide ; Valenti, Renato ; Marcucci, Rossella ; Carrabba, Nazario ; Migliorini, Angela ; Gensini, Gian Franco ; Abbate, Rosanna ; Antoniucci, David. / Residual platelet reactivity and outcomes with 5 mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention. In: International Journal of Cardiology. 2014 ; Vol. 176, No. 3. pp. 874-877.
@article{db563857b5b4459e854b25ada3da4aad,
title = "Residual platelet reactivity and outcomes with 5 mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention",
abstract = "Background In acute coronary syndrome (ACS) patients older than 75 years old, prasugrel 10 mg maintenance therapy has shown less clinical efficacy and higher risk of bleeding. In patients older than 75 years, a prasugrel dose of 5 mg should be used if treatment is deemed necessary. Objective The aim of this study was to compare platelet reactivity and outcomes in elderly patients receiving prasugrel 5 mg therapy with non-elderly patients receiving prasugrel 10 mg therapy.Methods and results Consecutive ACS patients undergoing percutaneous coronary intervention (PCI) treated with prasugrel were included. Of 718 patients, 228 (32{\%}) had ≤75 years and received prasugrel 5 mg/day. Residual platelet reactivity (RPR) was 47 ± 18{\%} and 36 ± 16{\%} in the elderly and non-elderly group, respectively (p = 0.001). High RPR (≤70{\%}) was found in 9{\%} and 2{\%} (p = 0.0001) in elderly and non-elderly patients, respectively. In the 6-month follow-up, there was no difference in mortality, stent thrombosis, and reinfarction rates between the 2 groups but a higher rate of TIMI minor bleeding (7.9{\%} vs 2.4{\%}; p = 0.001) in elderly as compared with younger patients. Age ≤75 years was independently associated with bleeding events (HR 2.162 [1.105-4.229]; p = 0.024).Conclusions Elderly patients receiving prasugrel 5 mg are more likely to experience high RPR than younger patients treated by prasugrel 10 mg. Despite the use of a reduced prasugrel maintenance dose and a higher level of RPR, elderly patients show increased risk of bleeding during prasugrel therapy as compared to younger patients.",
keywords = "Acute coronary syndrome, Bleeding, Elderly, Prasugrel, Stent",
author = "Guido Parodi and Benedetta Bellandi and Vincenzo Comito and Davide Capodanno and Renato Valenti and Rossella Marcucci and Nazario Carrabba and Angela Migliorini and Gensini, {Gian Franco} and Rosanna Abbate and David Antoniucci",
year = "2014",
month = "10",
day = "20",
doi = "10.1016/j.ijcard.2014.08.002",
language = "English",
volume = "176",
pages = "874--877",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Residual platelet reactivity and outcomes with 5 mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention

AU - Parodi, Guido

AU - Bellandi, Benedetta

AU - Comito, Vincenzo

AU - Capodanno, Davide

AU - Valenti, Renato

AU - Marcucci, Rossella

AU - Carrabba, Nazario

AU - Migliorini, Angela

AU - Gensini, Gian Franco

AU - Abbate, Rosanna

AU - Antoniucci, David

PY - 2014/10/20

Y1 - 2014/10/20

N2 - Background In acute coronary syndrome (ACS) patients older than 75 years old, prasugrel 10 mg maintenance therapy has shown less clinical efficacy and higher risk of bleeding. In patients older than 75 years, a prasugrel dose of 5 mg should be used if treatment is deemed necessary. Objective The aim of this study was to compare platelet reactivity and outcomes in elderly patients receiving prasugrel 5 mg therapy with non-elderly patients receiving prasugrel 10 mg therapy.Methods and results Consecutive ACS patients undergoing percutaneous coronary intervention (PCI) treated with prasugrel were included. Of 718 patients, 228 (32%) had ≤75 years and received prasugrel 5 mg/day. Residual platelet reactivity (RPR) was 47 ± 18% and 36 ± 16% in the elderly and non-elderly group, respectively (p = 0.001). High RPR (≤70%) was found in 9% and 2% (p = 0.0001) in elderly and non-elderly patients, respectively. In the 6-month follow-up, there was no difference in mortality, stent thrombosis, and reinfarction rates between the 2 groups but a higher rate of TIMI minor bleeding (7.9% vs 2.4%; p = 0.001) in elderly as compared with younger patients. Age ≤75 years was independently associated with bleeding events (HR 2.162 [1.105-4.229]; p = 0.024).Conclusions Elderly patients receiving prasugrel 5 mg are more likely to experience high RPR than younger patients treated by prasugrel 10 mg. Despite the use of a reduced prasugrel maintenance dose and a higher level of RPR, elderly patients show increased risk of bleeding during prasugrel therapy as compared to younger patients.

AB - Background In acute coronary syndrome (ACS) patients older than 75 years old, prasugrel 10 mg maintenance therapy has shown less clinical efficacy and higher risk of bleeding. In patients older than 75 years, a prasugrel dose of 5 mg should be used if treatment is deemed necessary. Objective The aim of this study was to compare platelet reactivity and outcomes in elderly patients receiving prasugrel 5 mg therapy with non-elderly patients receiving prasugrel 10 mg therapy.Methods and results Consecutive ACS patients undergoing percutaneous coronary intervention (PCI) treated with prasugrel were included. Of 718 patients, 228 (32%) had ≤75 years and received prasugrel 5 mg/day. Residual platelet reactivity (RPR) was 47 ± 18% and 36 ± 16% in the elderly and non-elderly group, respectively (p = 0.001). High RPR (≤70%) was found in 9% and 2% (p = 0.0001) in elderly and non-elderly patients, respectively. In the 6-month follow-up, there was no difference in mortality, stent thrombosis, and reinfarction rates between the 2 groups but a higher rate of TIMI minor bleeding (7.9% vs 2.4%; p = 0.001) in elderly as compared with younger patients. Age ≤75 years was independently associated with bleeding events (HR 2.162 [1.105-4.229]; p = 0.024).Conclusions Elderly patients receiving prasugrel 5 mg are more likely to experience high RPR than younger patients treated by prasugrel 10 mg. Despite the use of a reduced prasugrel maintenance dose and a higher level of RPR, elderly patients show increased risk of bleeding during prasugrel therapy as compared to younger patients.

KW - Acute coronary syndrome

KW - Bleeding

KW - Elderly

KW - Prasugrel

KW - Stent

UR - http://www.scopus.com/inward/record.url?scp=84908258507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908258507&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2014.08.002

DO - 10.1016/j.ijcard.2014.08.002

M3 - Article

VL - 176

SP - 874

EP - 877

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 3

ER -